Exelixis Inc

EXEL XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

12B

Short interest (May 15)

12.0%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.26%

↓ 0.4%

Available Shares

↓ 36.5%

Price Chart

Company Overview

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0000939767

Asset Type: CS

Market Data

Market Cap: $12,200,775,728

Employees: 1,077

Status: Active

Short Interest

Current Borrow Fee 0.26%

Range: 0.25% - 0.29%

Available Shares 4M

Range: 3.9M - 4.4M

Recent Changes

Fee Change: ↑ 2.7%

Available Change: ↑ 1.2%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime